ArticleRheumatology (Oxford, England)2021
Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden-an update on incidence and first prevalence estimate.
Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between infection and the onset of giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis.RMD open · 2023Pooled it
- The epidemiology of inflammatory rheumatic diseases in Germany in a European context: a systematic review to support workforce planning.EULAR rheumatology open · 2026Article
- Patient-reported outcomes and disease activity in giant cell arteritis: a longitudinal registry-based study.Rheumatology (Oxford, England) · 2026Article
- Association between antibiotic use and the onset of giant cell arteritis and polymyalgia rheumatica: A nested case-control study from E3N-European Prospective Investigation into Cancer and Nutrition.Journal of internal medicine · 2025Article
- Relationship between hemoglobin glycation index and all-cause mortality in patients with acute myocardial infarction: based on MIMIC-IV database.Diabetology & metabolic syndrome · 2025Article
- Giant cell arteritis in Finland from 2010 to 2020: incidence, developing diagnostic methods and disease presentation.Rheumatology advances in practice · 2025Article
- The Set up and the Triggers: An Update on the Risk Factors for Giant Cell Arteritis.Current neurology and neuroscience reports · 2024Review
- Dynamic molecular signatures of acute myocardial infarction based on transcriptomics and metabolomics.Scientific reports · 2024Article
- Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern Sweden.RMD open · 2024Article
- Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register.RMD open · 2024Article
- Current Perspectives in Giant Cell Arteritis: Can We Better Connect Pathogenesis and Treatment?Medicina (Kaunas, Lithuania) · 2024Review
- Temporal artery biopsy in giant cell arteritis: clinical perspectives and histological patterns.Frontiers in medicine · 2024Review
- The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic.Therapeutic advances in musculoskeletal disease · 2024Article
- Incidence of giant cell arteritis is associated with COVID-19 prevalence: A population-level retrospective study.Heliyon · 2023Article
- Utility of biomarkers and temporal artery biopsy length for investigating giant cell arteritis in Western Australia.International journal of rheumatic diseases · 2023Article
- Can active sun exposure decrease the risk of giant cell arteritis and polymyalgia rheumatica in women?Rheumatology advances in practice · 2023Article
- Giant cell arteritis: incidence and phenotypic distribution in Western Norway 2013-2020.Frontiers in medicine · 2023Article
- Temporal Artery Vascular Diseases.Journal of clinical medicine · 2022Review
- Global epidemiology of vasculitis.Nature reviews. Rheumatology · 2022Review
- Identification ofFrontiers in cardiovascular medicine · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterize the epidemiology of temporal artery biopsy-positive (TAB+) GCA, including trends in incidence, seasonal variation and prevalence in Skåne, the southernmost region of Sweden.
methodsAll histopathology reports of TABs from 1997 through 2019 were reviewed to identify patients diagnosed with TAB+ GCA. Incidence rates based on the 23-year period and the point-prevalence at 31 December 2014 were determined. An alternative prevalence calculation included only TAB+ GCA patients living in the study area and receiving immunosuppressant therapy on the point-prevalence date.
resultsOne thousand three hundred and sixty patients were diagnosed with TAB+ GCA (71% female). The average annual incidence 1997-2019 was 13.3 (95% CI: 12.6, 14.0) per 100 000 inhabitants aged ≥50 years and was higher in females (17.8; 95% CI: 16.7, 18.9) than in males (8.2; 95% CI: 7.4, 9.0). The age- and sex-standardized incidence declined from 17.3 in 1997 to 8.7 in 2019, with incidence ratio (IR) of 0.98 per year (95% CI: 0.98, 0.99). A seasonal variation was observed with higher incidence during spring than winter [IR = 1.19 (95% CI: 1.03, 1.39)]. The overall point-prevalence of TAB+ GCA was 127.1/100 000 (95% CI: 117, 137.3) and was 75.5 (95% CI: 67.7, 83.3) when including only patients receiving immunosuppressants.
conclusionOver the past 2 decades, the incidence of biopsy-confirmed GCA has decreased by ∼2% per year. Still, a high prevalence of GCA on current treatment was observed. More cases are diagnosed during spring and summer than in the winter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.